How do the results of TROPION-Lung01 Phase III trial change your practice in the management of locally advanced or metastatic NSCLC?  

Well, short-term the answer to this excellent question is simple- not at all as datopotomab deruxtecan is not approved in any context, therefore, we will need to await an FDA decision as to when/how dato (for short) can be integrated into our practices. However, why not daydream a little bit in the...